Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel
12 Mars 2018 - 1:30PM
Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the
appointment of John B. Moriarty, J.D., as executive vice president
and general counsel, effective immediately. Mr. Moriarty will
report to William Lis, chief executive officer, and will serve as
Portola’s chief legal officer, responsible for leading all legal,
regulatory, governance and compliance initiatives. He also will be
directly involved in strategic business transactions and corporate
expansion as a member of Portola’s Executive Committee.
“John’s appointment comes at a critical time for
Portola, as we execute on the successful launch of our first
medicine Bevyxxa (betrixaban), and continue to advance our two
other lead development programs, andexanet alfa and cerdulatinib,
through key clinical and regulatory milestones,” said Mr.
Lis. “His extensive legal and business expertise, as well as
his leadership track record, will be invaluable in addressing the
complex issues that accompany our transition into a global
commercial organization, and we are thrilled to welcome John to the
team.”
Mr. Moriarty joins Portola from Alexion
Pharmaceuticals where, as executive vice president and general
counsel for more than five years, he was responsible for overseeing
all global legal matters spanning 50 countries, as well as managing
Alexion’s Global Government Affairs and Global Corporate
Communications teams during his tenure. Previously, he was senior
vice president, general counsel and chief legal officer at Elan
Corporation plc, and served as a member of Elan’s Executive
Management team. Prior to joining Elan, Mr. Moriarty held positions
of increasing responsibility and leadership at Amgen. Earlier in
his career, he worked as an attorney in the healthcare practice of
a national law firm and was a healthcare fraud prosecutor in the
U.S. Attorney’s office and in the Virginia Attorney General’s
office.
"Portola has made substantial and rapid progress
in its commercial evolution and I am excited to join the team at
such a pivotal time,” said Mr. Moriarty. “Portola has a
well-recognized, science-based culture and I look forward to
working alongside such a talented and passionate team to deliver
new medicines that have the potential to transform patient care in
the fields of thrombosis and hematology.”
Mr. Moriarty received his J.D. from the
University of Georgia School of Law and his Bachelor of Arts from
the University of Virginia. He has served on the board of trustees
for the American Kidney Fund since 2015.
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s first medicine Bevyxxa® (betrixaban), an oral,
once-daily Factor Xa inhibitor, was approved by the U.S. Food
and Drug Administration in June 2017. The company is also
working to advance two clinical programs for andexanet alfa, a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a SYK/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective SYK inhibitors for inflammatory conditions.
For more information, visit http://www.portola.com and
follow the Company on Twitter @Portola_Pharma.
Investor Contact: Cara Miller Portola
Pharmaceuticals ir@portola.com
Media Contact: Laurie Masonson Pure
Communications lmasonson@purecommunications.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024